Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT Abstract #1341

Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.
Aim(s): To investigate the influence of lanreotide on the uptake of [68Ga]-DOTATATE in tumor- and normal tissue.
Materials and methods: 34 patients with metastatic/unresectable NET being treated with lanreotide and scheduled for [68Ga]-DOTATATE PET/CT are included. The PET/CT scan is made on the day before and the day after lanreotide injection in each patient. [68Ga]-DOTATATE uptake in the primary tumor, metastases, and normal tissue are quantified (SUVmax, mean, peak).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Else Aalbersberg
Keywords: DOTATATE

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1700 Distribution of 68Ga-HA-DOTATATE and 68Ga-DOTATATE in 343 Patients: Not the Same after All
Introduction: For the detection of neuroendocrine tumors, 68Ga-DOTATATE was developed but its use is restricted. This led to the development of 68Ga-HA-DOTATATE. In the literature, they are described as having comparable distributions.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MSc Else Aalbersberg
Keywords: HA-DOTATATE
#289 Gallium-68 DOTATATE PET CT Frequently Changes Patient Management or Staging When Compared with Indium-111 Octreotide in the Assessment of Neuroendocrine Tumors
Introduction: 68Ga-DOTATATE PET CT offers higher resolution than previous octreotide-labelled scintigraphic techniques, and the literature suggests increased sensitivity for the localization and staging of NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#1855 Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse